Solaymani-Dodaran, 373 patient favipiravir late treatment RCT: 19% higher mortality [p=0.54], 53% higher ventilation [p=0.15], and 19% higher ICU admission [p=0.56] https://c19p.org/solaymanidodaran
copied to clipboard
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107522
RCT late stage patients (median SpO2 89), 193 treated with favipiravir, 187 with lopinavir/ritonavir, showing no significant differences in mortality, intubation, or ICU admission.
|
risk of death, 19.2% higher, RR 1.19, p = 0.54, treatment 26 of 190 (13.7%), control 21 of 183 (11.5%).
|
|
risk of mechanical ventilation, 53.0% higher, RR 1.53, p = 0.15, treatment 27 of 190 (14.2%), control 17 of 183 (9.3%).
|
|
risk of ICU admission, 19.4% higher, RR 1.19, p = 0.56, treatment 31 of 190 (16.3%), control 25 of 183 (13.7%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Solaymani-Dodaran et al., 11 Mar 2021, Randomized Controlled Trial, Iran, peer-reviewed, 44 authors, this trial compares with another treatment - results may be better when compared to placebo.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.